A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management Hely ShahJulian SurujballiMark Clemons Review 06 November 2020 Pages: 533 - 547
The wisdom trial is based on faulty reasoning and has major design and execution problems Daniel B. Kopans Review 25 November 2020 Pages: 549 - 556
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer Mei-Yin C. PolleyRoberto A. Leon-FerreMatthew P. Goetz Review 03 January 2021 Pages: 557 - 566
Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging? Katelyn SchumacherMarc InciardiKelsey E. Larson Review 03 January 2021 Pages: 567 - 572
Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution Xiaoxian LiZhongliang MaMichael A. Cohen Preclinical study 17 October 2020 Pages: 573 - 581
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients Vanessa LattimoreMichael T. ParsonsLogan Walker Preclinical study Open access 28 October 2020 Pages: 583 - 590
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer Andrea ChobrutskiyBoris I. ChobrutskiyGeorge Blanck Preclinical study 12 November 2020 Pages: 591 - 600
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer Romain TropéeBárbara de la Peña AvalosEloïse Dray Preclinical study 12 November 2020 Pages: 601 - 614
Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer Khloud A. ElsharawyMaryam AlthobitiEmad A. Rakha Preclinical study Open access 08 November 2020 Pages: 615 - 627
Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy Shiwei LiuShiyan ZengPurong Zhang Preclinical study 09 November 2020 Pages: 629 - 638
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA) Katherine CliftonJingqin LuoCynthia Ma Preclinical study 20 November 2020 Pages: 639 - 646
Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray R. M. ParksM. A. AlbanghaliK-L. Cheung Preclinical study Open access 23 November 2020 Pages: 647 - 655
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC? Amparo Garcia-TejedorSergi Fernandez-GonzalezCatalina Falo Clinical trial 17 October 2020 Pages: 657 - 666
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis Roi WeiserWaqar HaqueV. Suzanne Klimberg Clinical trial 18 October 2020 Pages: 667 - 676
To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis? S. L. HerbertA. WöckelBRENDA study group Clinical trial Open access 26 October 2020 Pages: 677 - 684
Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial D. B. Raphael DanielaN. S. RussellL. J. Boersma Clinical trial Open access 24 October 2020 Pages: 685 - 695
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial Manuela RabaglioZhuoxin SunMeredith M. Regan Clinical trial 07 November 2020 Pages: 697 - 707
The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements Chirag ShahApril Zambelli-WeinerJerrod Nelms Clinical trial Open access 27 November 2020 Pages: 709 - 740
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial Rieneke T. LugtenbergStefanie de Grooton behalf of the Dutch Breast Cancer Research Group (BOOG) Clinical trial Open access 11 November 2020 Pages: 741 - 758
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase Jasgit C. SachdevPamela MunsterCarey Anders Clinical trial Open access 17 November 2020 Pages: 759 - 771
Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study Yin-Che LuDa-Wei HuangYi-Jiun Pan Epidemiology 16 October 2020 Pages: 773 - 783
Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features Adana A. M. LlanosSong YaoKitaw Demissie Epidemiology 16 October 2020 Pages: 785 - 798
Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis Yaokai WenXiangrong WuWenhua Liang Epidemiology 31 October 2020 Pages: 799 - 806
A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer Christine Brezden-MasleyKelly E. FathersKatarzyna J. Jerzak Epidemiology Open access 22 October 2020 Pages: 807 - 815
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer Gwen M. H. E. DackusKatarzyna JóźwiakSabine C. Linn Epidemiology Open access 28 October 2020 Pages: 817 - 830
Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women Asra N. ShaikKatrin KiavashMichele L. Cote Epidemiology 28 October 2020 Pages: 831 - 839
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes Fangyuan ZhaoBrenda CopleyDezheng Huo Epidemiology 27 October 2020 Pages: 841 - 849
Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients Renan GomesPricila da Silva SpinolaMiguel Angelo Martins Moreira Epidemiology 30 October 2020 Pages: 851 - 861
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function Katia KhouryFilipa LynceSandra M. Swain Brief report 05 January 2021 Pages: 863 - 868
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer Ciyu YangAngela G. ArnoldLiying Zhang Brief Report 16 January 2021 Pages: 869 - 877
New anti-HER2 agents for brain metastasis: histology-agnostic weapons? Paolo TarantinoAleix PratGiuseppe Curigliano Letter to the Editor 30 October 2020 Pages: 879 - 881
Letter to the editor regarding the article “Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer” Xishan ChenKangwen GuoJiong Lin Letter to the Editor 02 November 2020 Pages: 883 - 883
Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy Sadaf Alipour Letter to the Editor 28 October 2020 Pages: 885 - 886
Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis Andrea MessoriLaura BartoliElisa Ferracane Letter to the Editor 22 November 2020 Pages: 887 - 887
Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen C. Louwrens BraalKoen G. A. M. HussaartsRon H. J. Mathijssen Correction 23 November 2020 Pages: 889 - 889
Correction to: Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations Matthew S. KatzLinda McCallArmando E. Giuliano Correction 07 December 2020 Pages: 891 - 891